Pan-genotypic DAA salvage combination
Sofosbuvir with velpatasvir and voxilaprevir
Brand names: Vosevi
Adult dose
Dose: 400/100/100mg PO OD for 12 weeks
Route: PO
Frequency: OD
Clinical pearls
- Salvage therapy for HCV with prior DAA failure
- Screen HBV before
Contraindications
- Decompensated cirrhosis (Child-Pugh B/C)
- Concurrent rifampicin/strong inducers
- Concurrent ethinylestradiol (hepatotoxicity)
- Hypersensitivity
Side effects
- Headache
- Fatigue
- Diarrhoea
- HBV reactivation
- Hepatotoxicity
Interactions
- Many — see Liverpool HEP
- PPIs
- Statins
Monitoring
- LFTs
- HCV RNA
- HBV DNA
Reference: BNF; NICE TA507; EASL; https://bnf.nice.org.uk/drugs/sofosbuvir-with-velpatasvir-and-voxilaprevir/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators